Kevin Kinsella Overview
- Investor Type
-
Angel
- Investments
-
3
- Portfolio
-
1
- Exits
-
2

Kevin Kinsella General Information
Description
Mr. Kevin Kinsella is the Founder of Avalon Ventures. Mr. Kinsella is the Founder of Avalon Bioventures. He serves as Board Member at Eikonizo Therapeutics. He is a Co-Founder and serves as Board Member at Ankasa Regenerative Therapeutics. He served as Board Member at Avelas Biosciences. He is a Board Member at Jnana Therapeutics. He co-founded HauteDecor and served as its Chairman. He was the Founding Chairman at Landmark Graphics. He has specialized in the formation, financing, and development of more than 100 early-stage companies, including Athena Neurosciences Onyx Pharmaceuticals, Sequana, Vertex Pharmaceuticals, Synaptics, Vocera Communications, Amira Pharmaceuticals, Cardeas Pharma and Juliet Marine Systems. Mr. Kinsella was the Founding Chairman of Athena Neurosciences, Aurora Biosciences, Landmark Graphics, NeoRx, Onyx Pharmaceuticals, Synaptics, X-Ceptor, and Sequana Therapeutics. Prior to founding Avalon, Mr. Kinsella worked for Solar Turbines International (Caterpillar Tractor) where he was in charge of all international joint ventures, barter, and counter-trade. Previously, he was an advisor to the Peruvian government in National Nutrition Planning, ran a technology exchange program between the U.S. and Latin America based in Mexico City and taught algebra at the American High School in Beirut, Lebanon. He was also a guest op-ed columnist for the Boston Herald American. Mr. Kinsella is a graduate of the Massachusetts Institute of Technology ("MIT") with a Bachelor of Science degree in management, with minors in electrical engineering and political science. He holds a Master of Arts degree in international relations from the Johns Hopkins School of Advanced International Studies and conducted post-graduate work in political economy on a Rotary International Fellowship at the University of Stockholm, Sweden. Mr. Kinsella is a member of the Board of Directors of Cardeas Pharma. He also serves as Board Member at Juliet Marine Systems. He served as Founding Chairman at Vertex Pharmaceuticals.
Business Details
Primary Investor Type
Corporate Office
- 1134 Kline Street
- La Jolla
- San Diego, CA 92037
- United States
Kevin Kinsella Investments (3)
Company Name | Deal Date | Deal Type | Deal Size | Industry | Company Stage | Lead Partner |
---|---|---|---|---|---|---|
Eikonizo Therapeutics | 16-May-2018 | Seed Round | Drug Discovery | Pre-Clinical Trials | ||
Covigo | 01-Aug-2000 | Software Development Applications | Generating Revenue | |||
NearSpace | 10-Apr-2000 | Media and Information Services (B2B) | Generating Revenue |
Kevin Kinsella Exits (2)
Company Name | Exit Date | Exit Type | Exit Size |
---|---|---|---|
NearSpace | 01-Mar-2021 | Secondary Transaction - Private | |
Covigo | 30-Jul-2003 |
Kevin Kinsella Investments by Industry, Year, and Region
Kevin Kinsella FAQs
-
Who is Kevin Kinsella?
Kevin Kinsella is an angel Investor who has made 3 investments.
-
What kind of investor is Kevin Kinsella?
Kevin Kinsella is an angel investor.
-
What does Kevin Kinsella do?
As an angel investor, Kevin Kinsella invests personal money into promising companies, typically in exchange for equity.
-
How many board seats does Kevin Kinsella hold?
Kevin Kinsella holds 2 board seats including Eikonizo Therapeutics and X-Ceptor Therapeutics.
-
What has Kevin Kinsella invested in?
Kevin Kinsella has made numerous investments in companies like Eikonizo Therapeutics, Covigo, and NearSpace within the Drug Discovery, Software Development Applications, and Media and Information Services (B2B) industries.
-
What has Kevin Kinsella invested in recently?
Kevin Kinsella's latest investment was on 16-May-2018 in Eikonizo Therapeutics, a company within the Drug Discovery industry.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »